证券代码：300143 证券简称：盈康生命 公告编号：2025-037 及相关凭证要求公司清偿债务或提供相应担保。债权人未在规定期限内行使上述权 利的，不会因此影响其债权的有效性，相关债务（义务）将由公司根据原债权文件 的约定继续履行。 债权人可采用现场、邮寄等方式进行债权申报，具体方式如下： 1、申报时间：2025 年 8 月 2 日起 45 日内，9:30-11:30，13:30-16:30（双休日 及法定节假日除外） 盈康生命科技股份有限公司 关于使用公积金弥补亏损通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、通知债权人的原因 盈康生命科技股份有限公司（以下简称"公司"）于2025年7月16日召开第六 届董事会第十九次（临时）会议、2025年8月1日召开2025年第二次临时股东会，审 议通过了《关于公司使用公积金弥补亏损的议案》。具体内容详见公司于2025年7 月17日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司使用公积金弥补亏 损的公告》。 根据和信会计师事务所（特殊普通合伙）出具的和信审字（2025）第0 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-07-29 | 300143 | 盈康生命 | 9.90 | 145.42 | 1,439.66 华福证券有限责任 | | 华福证券有限责任 | | | | | | | | 公司东莞东莞大道 | 公司东莞东莞大道 | | | | | | | 证券营业部 | | 证券营业部 | 7月29日，盈康生命大宗交易成交145.42万股，成交额1439.66万元，占当日总成交额的12.87%，成交价9.9元，较市场收盘价 10.13元折价2.27%。 ...

Core Viewpoint - Yingkang Life has been awarded the "ESG Corporate Governance Pioneer Award" for its outstanding practices in environmental, social, and governance (ESG) areas, highlighting its commitment to integrating economic efficiency with social responsibility [1][4]. Governance - Yingkang Life emphasizes robust corporate governance as the foundation for sustainable development and social responsibility, showcasing a well-structured governance framework led by the board of directors and supported by various committees [4]. - The company has a diverse and professional governance structure, with female board members making up 28.57% and three independent directors, enhancing decision-making and oversight [4]. - A unique "five-in-one" risk management framework has been established to systematically identify and respond to multiple risks, including climate change and medical quality safety [4]. Innovation and Quality - The governance system supports technological innovation and improvement in medical quality, with a 2024 R&D investment of 54.52 million yuan, representing 3.50% of revenue [5]. - The company launched innovative projects such as a "multimodal medical imaging AI platform," significantly improving diagnostic efficiency and accuracy, with a total outpatient volume of 496,700 and a customer satisfaction rate of 99.12% [5]. Environmental Responsibility - Yingkang Life actively promotes "green healthcare," with an annual environmental investment of 4.4 million yuan and clear energy-saving and emission reduction targets, achieving a greenhouse gas emission intensity of 5.57 tons CO2e per million revenue [5]. - The company’s second phase of the Guangci Hospital project employs advanced energy-saving technologies, achieving a 10% energy-saving rate [5]. Social Responsibility - The company focuses on creating a "happy workplace," providing 2,207 jobs with a female employee ratio of 66.11% and hiring nine disabled individuals [6]. - Employee development is prioritized, with a 100% training coverage rate and an average training duration of 48.15 hours per employee, alongside various employee welfare activities [6]. Recognition and Future Outlook - Yingkang Life has received high ESG ratings, including a score of 55 from S&P Global CSA and an AA rating from Wind ESG, ranking first in its industry [6]. - The company aims to deepen governance reforms, enhance risk management, accelerate medical technology innovation, and expand public welfare services by 2025, striving to become a global benchmark for sustainable development in the healthcare sector [6].

Core Viewpoint - The use of capital reserve to cover losses by listed companies is being implemented, but it is essential to balance the interests of all parties involved, particularly the protection of creditors' rights [1][2][3] Group 1: Regulatory Framework - The new Company Law stipulates that companies must first use discretionary and statutory reserves before utilizing capital reserves to cover losses [1] - The Ministry of Finance issued a notification that outlines the financial regulations regarding the use of capital reserves, including the requirement for board resolutions to be submitted for shareholder approval [1] - The notification emphasizes the need to protect creditor interests, mandating companies to notify creditors within thirty days of the shareholder resolution [1][2] Group 2: Creditor Protection - Companies must provide reasonable assessments of their debt repayment capabilities to creditors to mitigate misunderstandings [2] - The "unsettled defense right" under the Civil Code allows creditors to suspend contract obligations if they have evidence of the debtor's deteriorating financial condition [2] - If the use of capital reserves leads to a decline in the core capital adequacy ratio by more than 30%, creditors may have the right to demand collateral or accelerate debt repayment [2] Group 3: Impact on Financial Health - Utilizing capital reserves does not genuinely affect a company's actual profitability, and stricter regulations may be necessary to manage the interests of various stakeholders [3] - Companies with significant losses or those classified as ST (Special Treatment) should be prohibited from using capital reserves to cover losses, while strategic emerging industries with high R&D intensity may have relaxed rules [3] - Companies are restricted from share buybacks or large cash dividends within 12 months after using capital reserves to cover losses [3] Group 4: Recommendations for Improvement - Regulatory bodies should enhance guidance and monitoring of companies using capital reserves to ensure stable profitability [3] - Companies should develop actionable plans for turning losses into profits and be transparent in their operations to regain market trust [3] - The use of capital reserves should not serve as a tool for concealing financial issues but should aim to facilitate recovery and compliance within a secure framework [3]

Group 1 - The high-pressure oxygen chamber concept increased by 1.55%, ranking second among concept sectors, with three stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading gainers in the high-pressure oxygen chamber sector were International Medicine and Yinkang Life, which rose by 0.93% and 0.20% respectively [1] - The sector saw a net inflow of 0.50 billion yuan from main funds, with Tiebian Heavy Industry receiving the highest net inflow of 1.03 billion yuan [2][3] Group 2 - The main fund inflow ratios for Tiebian Heavy Industry, International Medicine, and Jinling Pharmaceutical were 29.36%, 10.10%, and 5.54% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed varied results, with Tiebian Heavy Industry leading in both price increase and fund inflow [3][4] - Stocks such as Weiao and Innovation Medical experienced significant declines, with net outflows of -3214.35 million yuan and -4427.60 million yuan respectively [4]

Group 1 - The high-pressure oxygen chamber concept increased by 2.63%, ranking 10th among concept sectors, with five stocks rising, including a 20% limit-up for Tiedao Heavy Industry [1] - Notable gainers in the high-pressure oxygen chamber sector include Innovation Medical and Samsung Medical, which rose by 3.29% and 0.96% respectively [1] - The sector experienced a net inflow of 170 million yuan from main funds, with Tiedao Heavy Industry receiving the highest net inflow of 120 million yuan [2] Group 2 - The top stocks by net inflow ratio in the high-pressure oxygen chamber sector are Tiedao Heavy Industry at 39.19%, International Medical at 4.88%, and Samsung Medical at 4.16% [3] - The trading volume and turnover rates for key stocks in the sector indicate significant investor interest, with Tiedao Heavy Industry showing a turnover rate of 0.97% [3] - Decliners in the sector included Dahu Co., which fell by 0.55%, and Aoyang Health, which decreased by 0.50% [4]

证券代码：300143 证券简称：盈康生命 公告编号：2025-035 沈旭东先生符合《公司法》《公司章程》规定的有关职工代表董事任职资格和 条件。沈旭东先生当选公司职工代表董事后，公司第六届董事会中兼任公司高级管 理人员以及由职工代表担任的董事人数未超过公司董事总数的二分之一，符合相关 法律法规的要求。 盈康生命科技股份有限公司 关于董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、关于非独立董事辞任的情况 盈康生命科技股份有限公司（以下简称"公司"）董事会收到公司非独立董事 沈旭东先生的书面辞任报告。因公司内部工作调整，沈旭东先生申请辞去公司第六 届董事会非独立董事职务，原定任期到2026年9月27日，辞任后仍担任公司相关职 务。沈旭东先生的辞任不会导致公司董事会人数低于法定最低人数，其辞任报告自 送达公司董事会之日起生效。 截至本公告披露日，沈旭东先生持有公司股份41,497股，占公司总股本的 0.0055%。沈旭东先生此次职位变动后，将继续严格遵守《公司法》《上市公司董 事和高级管理人员所持本公司股份及其变动管理规则 ...

Group 1 - The high-pressure oxygen chamber concept increased by 3.78%, ranking 8th among concept sectors, with 8 stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading stocks in the high-pressure oxygen chamber sector included Weiao Co., International Medicine, and Dahu Co., which rose by 3.80%, 3.24%, and 2.44% respectively [1] - The high-pressure oxygen chamber sector saw a net inflow of 152 million yuan from main funds, with 6 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow [2] Group 2 - The top net inflow stock was Tiebian Heavy Industry, with a net inflow of 60.89 million yuan, followed by International Medicine, Samsung Medical, and Aoyang Health with net inflows of 57.53 million yuan, 42.20 million yuan, and 22.89 million yuan respectively [2] - In terms of net inflow ratios, Aoyang Health, Tiebian Heavy Industry, and International Medicine had the highest ratios at 15.77%, 14.47%, and 11.68% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed significant activity, with Tiebian Heavy Industry achieving a daily increase of 19.90% and a turnover rate of 1.60% [3]

Group 1 - The company plans to use a total of 1.458 billion yuan from its surplus and capital reserves to cover accumulated losses, primarily due to asset impairment from acquisitions made before Haier's takeover [1] - The losses are attributed to prior years' asset impairment losses and investment losses from the transfer of subsidiary equity, mainly related to assets acquired before Haier's involvement [1] - This financial restructuring is a common practice for listed companies to optimize their financial structure and is in line with the new Company Law and relevant guidelines from the Ministry of Finance [1] Group 2 - The financial adjustment is not a reactive measure due to operational pressure; the company has achieved steady profitability, with a net profit of 100 million yuan in 2023, a year-on-year increase of 116.9% [2] - Projected net profit for 2024 is 115 million yuan, reflecting a growth of 14.92%, and the company started 2025 with a strong first quarter net profit of 29.99 million yuan [2] - The company is entering a new development phase, driven by the dual engines of medical services and high-end medical devices, enhanced by "medical + AI" technology [2]

Core Viewpoint - Yingkang Life plans to use 1.458 billion yuan from its capital reserve to offset accumulated losses, aiming to clear its balance sheet losses and reset its undistributed profits to zero, which reflects a strategic financial maneuver rather than a fundamental operational recovery [2][3] Financial Strategy - The company reported a net profit of 29.99 million yuan and revenue of 409 million yuan in Q1 2025, indicating initial success in its restructuring efforts, but this profit is insufficient to cover previous substantial losses [3] - The use of capital reserves to offset losses is a compliant financial arrangement that may restore the company's refinancing capabilities and future profit distribution potential [2] Operational Concerns - Despite the accounting maneuver, the actual operational performance remains critical; the company must demonstrate sustainable profitability rather than relying on one-time financial improvements [3] - The significant losses in recent years stem from asset impairments and investment losses related to subsidiary equity disposals, highlighting weaknesses in investment management and business strategy [2] Market Sentiment - The market reaction to loss offsetting strategies is mixed; while it may enhance the potential for future dividends and provide some stock price support, investors remain focused on the company's fundamental business model and risk management capabilities [3] - The case of Yingkang Life serves as a cautionary tale for other listed companies regarding the risks of aggressive expansion and diversification without sound management practices [3] Future Outlook - The ability of Yingkang Life to truly pivot and establish a growth trajectory will be a key focus for market observers, as financial adjustments alone cannot ensure long-term value [3]